NS-136 explained

Routes Of Administration:Oral
Class:Muscarinic acetylcholine M4 receptor positive allosteric modulator
Synonyms:NS136

NS-136 is a selective muscarinic acetylcholine M4 receptor positive allosteric modulator which is under development for the treatment of schizophrenia and Alzheimer's disease.[1] [2] [3] It has been found to possess pro-cognitive effects in rodents. The drug is under development by NeuShen Therapeutics. As of May 2024, it is in phase 1 clinical trials for schizophrenia and is in the preclinical stage of development for Alzheimer's disease. The drug is a small molecule, but its chemical structure does not seem to have been disclosed.

See also

Notes and References

  1. Web site: NS 136 . AdisInsight . Springer Nature Switzerland AG . 15 May 2024 . 21 October 2024.
  2. Web site: Delving into the Latest Updates on NS-136 with Synapse . Synapse . 19 September 2024 . 21 October 2024.
  3. Yohn SE, Harvey PD, Brannan SK, Horan WP . The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia . Frontiers in Psychiatry . Frontiers Media SA . 15 . 4 October 2024 . 1664-0640 . 10.3389/fpsyt.2024.1421554 . free . 11525114 .